Opinion|Videos|March 21, 2024
Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
Advertisement
Episodes in this series
Advertisement
Related to this article
Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
Dana-Farber, Mass General Brigham, and Broad Institute researchers uncovered clues to why colorectal cancer can be more aggressive in younger people.
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5